Enhanced anti-inflammatory effects of celecoxib from a transdermally applied nanoemulsion

Pharmazie

Volumn 64, Issue 4, 2009, Pages 258-259

  Shakeel, Faiyaz ^a   Baboota, S ^b   Ahuja, A ^b   Ali, J ^b   Shafiq, S ^c  

^a Alarab Medical University   (Libyan Arab Jamahiriya)

^b HAMDARD UNIVERSITY   (India)

^c ZYDUS RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EXCIPIENT; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; GEL; MALE; NANOEMULSION; NONHUMAN; PAW EDEMA; RAT; ANIMAL; EMULSION; INTRADERMAL DRUG ADMINISTRATION; SKIN ABSORPTION; WISTAR RAT;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; EMULSIONS; EXCIPIENTS; MALE; NANOPARTICLES; PYRAZOLES; RATS; RATS, WISTAR; SKIN ABSORPTION; SULFONAMIDES;

EID: 66449121979     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.8282     Document Type: Article

References (15)

1. Ahmed M, Ramadan W, Rambhu D, Shakeel F (2008) Potential of nano-emulsions for intravenous delivery of rifampicin. Pharmazie 63: 806-811.
2. Baboota S, Alazaki A, Kohli K, Ali J, Dixit N, Shakeel F (2007a) Development and evaluation of a microemulsion formulation for transdermal delivery of terbenafine. PDA J Pharm Sci Tech 61: 276-285.
3. Baboota S, Shakeel F, Ahuja A, Ali J, Shafiq S (2007b) Design, development and evaluation of novel nanoemulsion formulation for transdermal potential of celecoxib. Acta Pharm 8: 316-332.
4. Baboota S, Shakeel F, Kohli K (2006) Development and evaluation of once-a-day transdermal gels of diclofenac diethylamine. Methods Find Exp Clin Pharmcol 28: 109-114.
5. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M (2007a) Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 66: 227-243.
6. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M (2007b) Design and development of ramipril nanoemulsion formulation: in vitro and In vivo assessment. J Biomed Nanotech 3: 28-44.
7. Shafiq S, Shakeel F, Talegaonkar S, Ali J, Baboota S, Ahuja A, Khar RK, Ali M (2007c) Formulation development and optimization using nano-emulsion technique: a technical note. AAPS Pharm Sci Tech 8: E 28.
8. Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S (2007) Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS Pharm Sci Tech 8: E104.
9. Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S (2008a) Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion formulation. J Nanobiotech 6: E8.
10. Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S (2008b) Celecoxib nano-emulsion: Skin permeation mechanism and bioavailability assessment. J Drug Target 16: 733-740.
11. Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S (2008c) Skin permeation mechanism of aceclofenac using novel nanoemulsion formulation. Pharmazie 63: 580-584.
12. Shakeel F, Baboota S, Ahuja A, Ali J, Faisal MS, Shafiq S (2008d) Stability evaluation of celecoxib nanoemulsion containing Tween 80. Thai J Pharm Sci 32: 4-9.
13. Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S (2009) Celecoxib nano-emulsion for transdermal drug delivery: Characterization and in vitro evaluation. J Disp Sci Tech 30: 6-11 (In Press).
14. Stichtenoth DO, Frolich JC (2003) The second generation of COX-2 inhibitors. Drugs 63: 33-45.
15. Winter CA (1965) Anti-inflammatory testing methods: Comparative evaluation of indomethacin and other agents. Nonsteroid Anti-inflammat Drugs 82: 190-202.